Marine Drugs (Feb 2022)

Deoxyvasicinone with Anti-Melanogenic Activity from Marine-Derived <i>Streptomyces</i> sp. CNQ-617

  • Se-eun Lee,
  • Min-ju Kim,
  • Prima F. Hillman,
  • Dong-Chan Oh,
  • William Fenical,
  • Sang-Jip Nam,
  • Kyung-Min Lim

DOI
https://doi.org/10.3390/md20020155
Journal volume & issue
Vol. 20, no. 2
p. 155

Abstract

Read online

The tricyclic quinazoline alkaloid deoxyvasicinone (DOV, 1) was isolated from a marine-derived Streptomyces sp. CNQ-617, and its anti-melanogenic effects were investigated. Deoxyvasicinone was shown to decrease the melanin content of B16F10 and MNT-1 cells that have been stimulated by α-melanocyte-stimulating hormone (α-MSH). In addition, microscopic images of the cells showed that deoxyvasicinone attenuated melanocyte activation. Although, deoxyvasicinone did not directly inhibit tyrosinase (TYR) enzymatic activity, real-time PCR showed that it inhibited the mRNA expression of TYR, tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2). In the artificial 3D pigmented skin model MelanodermTM, deoxyvasicinone brightened the skin significantly, as confirmed by histological examination. In conclusion, this study demonstrated that the marine microbial natural product deoxyvascinone has an anti-melanogenic effect through downregulation of melanogenic enzymes.

Keywords